

Helping guide confident treatment decisions

For ER+, HER2– early-stage breast cancer

Partial
**MEDICARE
REBATE**
Available

Only available at

AUSTRALIAN

 **Clinicalabs**



What is EndoPredict?

After learning that you have breast cancer, it can be challenging to understand all your options for testing and treatment. Using your first biopsy, the amount of protein made by different genes was checked.

These genes were:

- Estrogen receptor (ER)
- Progesterone receptor (PR)
- Human epidermal growth factor receptor 2 (HER2)

Knowing whether your tumour makes these proteins, along with additional testing like EndoPredict, can help determine the best course of treatment.

EndoPredict is a prognostic test for women with early-stage, ER+, HER2– primary breast cancer.

EndoPredict calculates the chance that your cancer will return in the 10 years after treatment, offering important information about how aggressive your cancer is. Knowing this information can help you and your doctor make well-informed choices about your treatment, including whether or not chemotherapy will benefit you in addition to standard endocrine therapy.

Why does your doctor trust EndoPredict?

- EndoPredict provides highly accurate test results for confident, long-term decision-making.
- It uses genetic information and other tumour features to calculate your personal results.
- Medical guidelines include EndoPredict.
- EndoPredict accurately identifies more patients who may safely forgo chemotherapy.

Knowing your risk is important for your treatment


After surgery, you will make treatment choices with the goal of lowering the chance that your cancer will return, or recur, in the future. For patients like you who have ER+ breast cancer, endocrine therapy is standard or routine. It can lower the risk of the cancer returning—also called the risk of recurrence—by almost half. Some patients will receive both endocrine therapy and chemotherapy. Your doctor will weigh several factors to decide if adding chemotherapy would benefit you further.

What do your EndoPredict test results mean?

The EndoPredict test results provide details about your specific breast cancer, including the risk of your cancer returning in the 10 years after treatment if you do not have chemotherapy. Your results will clearly note whether you are **low risk** or **high risk**.

- A **low-risk** result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is **LOW**.
- A **high-risk** result means that if you do not have chemotherapy, the risk of your cancer returning is **HIGH**.

Creating a treatment plan that's right for you



For patients who have a **long-term risk of recurrence that is low**, adding chemotherapy is unlikely to improve the absolute benefit by much.

For patients who have a **long-term risk of recurrence that is high**, adding chemotherapy may help significantly lower the risk.

Getting accurate information that is unique to your specific cancer can help you make the right treatment choice.

How to pay for your EndoPredict test

A partial Medicare rebate is available for EndoPredict, subject to Medicare eligibility criteria.

Patients are required to pay prior to our laboratory conducting the test. Clinical Labs will contact you via SMS or phone call with payment instructions when it is time to make the payment. After making the payment online, Clinical Labs will send you a receipt, which you can use to claim the partial Medicare rebate directly from Medicare.



For current pricing and further information, please visit clinicallabs.com.au/endopredict-patient or scan the QR code.



1300 134 111

clinicallabs.com.au